期刊文献+

不同佐剂增强小鼠黑色素瘤瘤苗抗瘤细胞免疫效应的比较 被引量:1

The Cell-mediated Immunoenhancement of Different Adjuvants on the Murine Melanoma Vaccine
下载PDF
导出
摘要 目的评价5种不同配方佐剂在低免疫原性小鼠黑色素瘤瘤苗保护性免疫中的细胞免疫增强作用。方法实验组用5种不同配方的佐剂(FCA,FCA+IL-2+GM-CSF,FIA+IL-2+GM-CSF,FIA+SWZY,FIA+SWZY+IL-2+GM-CSF)和照射灭活的D5黑色素瘤细胞制成瘤苗免疫小鼠,对照组免疫用单纯灭活D5黑色素瘤细胞。末次免疫后3天各组取半数动物检测DTH反应、NK细胞活性及特异性CTL活性,剩余半数动物接种活D5黑色素瘤细胞,3周后再次检测上述各免疫学参数。结果与对照组相比,经免疫后的各实验组DTH反应、NK细胞活性、CTL活性均明显升高(P<0.05),但成瘤后随肿瘤增大,则呈下降趋势。结论5种佐剂配方制成的瘤苗均能诱导免疫小鼠对低免疫原性肿瘤的细胞免疫应答。其中佐剂SWZY和FCA增强免疫的效果相当,而毒副作用较小,可望成为一种人类肿瘤免疫治疗的新型佐剂。 Objective To investigate the cell-mediated immunity enhancement effect of different adjuvants on the immunoprevention of poorly immunogenic routine melanoma vaccine. Methods Mice were immunized with inactivited D5 melanoma cells combined with five different adjuvants (FCA ,FCA + IL-2 + GM-CSF ,FIA + IL-2 + GM-CSF, FIA + SWZY, FIA + SWZY + IL-2 + GM-CSF) respectively and the control without adjuvants. 3 days after immunization, DTH response,NK cell activity and specific CTL activity were assayed in half of the mice. The rest were inoculated with the llve 135 tumor cells, 3 weeks after tumor inoculation, the same immunological parameters were measured. Results DTH response, NK cell activity and CTL activity of all the experimental groups were higher than that in the control group (P〈0. 05), but decreased after the tumor grew larger. Conclusion Adjuvant FCA, FIA, IL-2, GM-CSF, SWZY could enhance the cell-mediated immune responses against poorly immunogenic tumor. The adjuvant SWZY could strengthen immunoresponses similar to FCA, but had almost no harmful sideeffect, which might be a promising adjuvant for cancer vaccine.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2007年第4期259-261,共3页 Cancer Research on Prevention and Treatment
基金 国家自然科学基金资助项目(30370549)
关键词 佐剂 肿瘤疫苗 黑色素瘤 Adjuvant Tumor vaccine Melanoma
  • 相关文献

参考文献9

  • 1Schwaab T,Tretter CP,Gibson JJ,et al.Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma[J].J Urol,2004,171(3):1036-1042.
  • 2秦燕,宋三泰.恶性肿瘤的瘤苗免疫治疗[J].国外医学(肿瘤学分册),2002,29(1):36-39. 被引量:2
  • 3Huang L,Ohno T.Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model[J].Cancer Lett,2003,202(2):153-159.
  • 4Hu HM,Urba WJ,Fox BA.Gene-modified tumor vaccine with therapeutic potential shifts tumor specific T cell response from a type 2 to a type 1 cytokine profile[J].J Immunol,1998,161(6):3033-3041.
  • 5王艳,周乐,耿宜平,司履生,王一理.低免疫原性肿瘤可诱导调节性T细胞增生[J].中华病理学杂志,2005,34(9):583-587. 被引量:3
  • 6齐旭,周伊,王一理,马军,闫晓彩,韩俊宏,来宝长,尚宁宽,耿宜萍,司履生.同系细胞瘤苗对低免疫原性小鼠黑色素瘤治疗作用的研究[J].中国肿瘤生物治疗杂志,2002,9(1):60-61. 被引量:5
  • 7Smyth MJ,Hayakawa Y,Takeda K,et al.New aspects of natural-killer-cell surveillance and therapy of cancer[J].Nat Rev Cancer,2002,2(11):850-861.
  • 8Harris JE,Ryan L,Hoover HC Jr,et al.Adjuvant active specific immunotherapy for stage Ⅱ and Ⅲ colon cancer with an autologous tumor cell vaccine:Eastern Cooperative Oncology Group Study E5283[J].J Clin Oncol,2000,18(1):148-157.
  • 9刘英.肿瘤抗原特异性细胞毒T细胞和肿瘤免疫治疗[J].中国实验血液学杂志,2004,12(2):244-248. 被引量:4

二级参考文献60

  • 1[1]Hu HM,Urba W J,Fox BA.Gene-modified rumor vaccine with therapeutic potential shifts tumor specific T cell response from a type 2 to a type 1 cytokine profile[J].J Immunology,1998,161:3033-3041.
  • 2[2]Sinkovics JG,Horvath JC.Vaccination against human cancers[J].Int J Oncol,2000,16(1): 81-96.
  • 3[3]Hsueh EC,Nathanson L,Foshag LJ,et al.Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with intransit melanoma metastasis [ J].Cancer,1999,85: 2160-2169.
  • 4[4]Parmiani G,Rodolfo M,Melani C.Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal[J].Hum Gene Ther,2000,11(9): 1269-1275.
  • 5Pittet MJ, Zippelius A, Speiser DE, et al. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol,2001;166:7634-7640
  • 6Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating tumorreactive CD8 (+) T cells in melanoma patients contain a CD45RA (+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res,2002;62:1743-1750
  • 7Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cells clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration and antitumor effect of transferred T cells. Proc Natl Ac ad Sci U
  • 8Jager E, Maeurer M, Hohn H, et al. Clonal eapansion of Melan Aspecific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer,2000;86:538-547
  • 9Coulie PG, Karanikas V, Colau D, et al. A momoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.Proc Natl Sci USA,2001;98:10290-10295
  • 10Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother,2001;50:3-15

共引文献10

同被引文献14

  • 1王淑瑞,齐浩,刘建强,郭伟.B16黑色素瘤移植模型的建立[J].西安文理学院学报(自然科学版),2006,9(1):18-20. 被引量:10
  • 2周伊,齐旭,肖菊香,来宝长,司履生,王一理.新型佐剂SWZY对弱免疫原性小鼠黑色素瘤瘤苗的免疫增强作用[J].细胞与分子免疫学杂志,2006,22(4):526-529. 被引量:4
  • 3Mei HF,Jin XB, Shen J, et al. 15-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the gr~wtil of implanted routine melanoma in vivo [ J ]. PloS One, 2012,7 (2) :e31328.
  • 4Eun-Young Lee, Kyong-Su Park, Yong Song Gho,et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis[ J ]. PIoS One ,2012,7 ( 3 ) : e33330.
  • 5Colavecchia SB, Jolly A, Mundo SL, et al. Effect of lipoarabinomannan from mycobacterium avium subsp auium in freund's incomplete adjuvant on the immune response of cattle[ J ]. Braz J Med Biol Res,2012,45(2):139-146.
  • 6Wilton DJ,Ghosh M,Chary KV,et al. Structural change in a B- DNA helix with hydrostatic pressure[ J ]. Nucleic Acids Res,2008, 36( 12 ) :4302-4307.
  • 7Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation [ J ]. J Exp Med, 2004,200 (3) :287-295.
  • 8Ferrari S, Rovati B, Porta C, et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard or high-dose chemotherapy plus granulocyte-colony stimulating factor [ J ]. Cancer Immunol Immunother, 2003,52 (6) :359-366.
  • 9Fehniger TA, Cooper MA, Nuovn GJ, et al. CD56 bright naturalkiller cells are present in human lymph nodes and are activated by T cell-derived 1L-2 : a potential new link between adaptive and innate immunity. [ J ]. Blood ,2003,101 (8) :3052-3057.
  • 10Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic celL/tumor fusing cells results in cellular and homoral antitumor immune reponses in patients with multipul myeloma [ J ]. Blood, 2011,117(2) :393-402.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部